Currently in the clinic, the use of the biomarker-guided PD-1 inhibitor immunotherapy is mainly guided by the PD-1/PD-L1 expression level, tumor mutation burden (TMB), and tumor microsatellite instability (MSI) [6, 7]. The gene discussed is PDCD1; the disease is neoplasm.